RU2006115558A - Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы - Google Patents
Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы Download PDFInfo
- Publication number
- RU2006115558A RU2006115558A RU2006115558/04A RU2006115558A RU2006115558A RU 2006115558 A RU2006115558 A RU 2006115558A RU 2006115558/04 A RU2006115558/04 A RU 2006115558/04A RU 2006115558 A RU2006115558 A RU 2006115558A RU 2006115558 A RU2006115558 A RU 2006115558A
- Authority
- RU
- Russia
- Prior art keywords
- ring
- aliphatic group
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 8
- 102000012479 Serine Proteases Human genes 0.000 title claims 5
- 108010022999 Serine Proteases Proteins 0.000 title claims 5
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims 95
- 229910052757 nitrogen Inorganic materials 0.000 claims 65
- 125000001424 substituent group Chemical group 0.000 claims 62
- 229910052760 oxygen Inorganic materials 0.000 claims 57
- 229910052717 sulfur Inorganic materials 0.000 claims 57
- 125000005842 heteroatom Chemical group 0.000 claims 53
- 125000000623 heterocyclic group Chemical group 0.000 claims 52
- 150000001875 compounds Chemical class 0.000 claims 51
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 49
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 47
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 45
- 125000004429 atom Chemical group 0.000 claims 36
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- -1 1,2-methylenedioxy Chemical group 0.000 claims 24
- 125000000165 tricyclic carbocycle group Chemical group 0.000 claims 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 8
- 125000006721 (C5-C10) heteroaryl (C1-C6) alkyl group Chemical group 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000464 thioxo group Chemical group S=* 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 4
- 239000010839 body fluid Substances 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 3
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 102000007501 Thymosin Human genes 0.000 claims 2
- 108010046075 Thymosin Proteins 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229940044627 gamma-interferon Drugs 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 1
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 claims 1
- 108010052832 Cytochromes Proteins 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000010241 blood sampling Methods 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- 0 CCCCC([C@@](C)CCC)[C@@]1*2(CCCC2)C1C Chemical compound CCCCC([C@@](C)CCC)[C@@]1*2(CCCC2)C1C 0.000 description 6
- ZPRZWFMMXITIEN-UHFFFAOYSA-N CC(C(C1)N(C)C(C2)C1C1C2CCCC1)=O Chemical compound CC(C(C1)N(C)C(C2)C1C1C2CCCC1)=O ZPRZWFMMXITIEN-UHFFFAOYSA-N 0.000 description 1
- PSYGDLIDUQPOKY-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1cc(cccc2)c2cc1)=O Chemical compound CC(C(C1)N(C)CC1OCc1cc(cccc2)c2cc1)=O PSYGDLIDUQPOKY-UHFFFAOYSA-N 0.000 description 1
- MSALOQXDUIXDDG-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1cccc2c1cccc2)=O Chemical compound CC(C(C1)N(C)CC1OCc1cccc2c1cccc2)=O MSALOQXDUIXDDG-UHFFFAOYSA-N 0.000 description 1
- DNCOHZODLHDVGD-UHFFFAOYSA-N CC(C(C1)N(C)CC1OCc1ccccc1)=O Chemical compound CC(C(C1)N(C)CC1OCc1ccccc1)=O DNCOHZODLHDVGD-UHFFFAOYSA-N 0.000 description 1
- CJJIOQWQNCHWOP-MRTLOADZSA-N CC(C(C1)N(C)C[C@@H]1[n](nc1-c2ccccc2)nc1-c1ccccc1)=O Chemical compound CC(C(C1)N(C)C[C@@H]1[n](nc1-c2ccccc2)nc1-c1ccccc1)=O CJJIOQWQNCHWOP-MRTLOADZSA-N 0.000 description 1
- WTYLAGIFKVNSEQ-UHFFFAOYSA-N CC(C(C=CC1CC2NC)N1C2=O)=O Chemical compound CC(C(C=CC1CC2NC)N1C2=O)=O WTYLAGIFKVNSEQ-UHFFFAOYSA-N 0.000 description 1
- PENAODPZFZITCT-UHFFFAOYSA-N CC(C(CC1)N(C2)C1CCC2NC)=O Chemical compound CC(C(CC1)N(C2)C1CCC2NC)=O PENAODPZFZITCT-UHFFFAOYSA-N 0.000 description 1
- PRJWZCFBRYCMOE-UHFFFAOYSA-N CC(C(CC1)N(C2=O)N1CCCN2NC)=O Chemical compound CC(C(CC1)N(C2=O)N1CCCN2NC)=O PRJWZCFBRYCMOE-UHFFFAOYSA-N 0.000 description 1
- VMTLDTWEMMJNCU-UHFFFAOYSA-N CC(C(CC12)N(C)C1NC1C2NCCC1)=O Chemical compound CC(C(CC12)N(C)C1NC1C2NCCC1)=O VMTLDTWEMMJNCU-UHFFFAOYSA-N 0.000 description 1
- UPXMTVUDVIMOMT-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2cccn1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2cccn1)=O UPXMTVUDVIMOMT-UHFFFAOYSA-N 0.000 description 1
- MPZORVHGOJJCBE-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2ccnc1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2ccnc1)=O MPZORVHGOJJCBE-UHFFFAOYSA-N 0.000 description 1
- APKLCLCQXYADRE-UHFFFAOYSA-N CC(C(CC12)N(C)C1Nc1c2cncc1)=O Chemical compound CC(C(CC12)N(C)C1Nc1c2cncc1)=O APKLCLCQXYADRE-UHFFFAOYSA-N 0.000 description 1
- YPQOSOMZNCTZIV-UHFFFAOYSA-N CC(C(CCC1)N(C2=O)N1CCCN2NC)=O Chemical compound CC(C(CCC1)N(C2=O)N1CCCN2NC)=O YPQOSOMZNCTZIV-UHFFFAOYSA-N 0.000 description 1
- WCWAJWJVMPOYLI-UHFFFAOYSA-N CC(C(CCC1=NC=C2NC)N1C2=O)=O Chemical compound CC(C(CCC1=NC=C2NC)N1C2=O)=O WCWAJWJVMPOYLI-UHFFFAOYSA-N 0.000 description 1
- KVVPVHPVSILHSX-UHFFFAOYSA-N CC(C(CCCC1=NC=C2NC)N1C2=O)=O Chemical compound CC(C(CCCC1=NC=C2NC)N1C2=O)=O KVVPVHPVSILHSX-UHFFFAOYSA-N 0.000 description 1
- PMGQDOGUGBNIHE-UHFFFAOYSA-N CC(C(CNC1CC2NC)N1C2=O)=O Chemical compound CC(C(CNC1CC2NC)N1C2=O)=O PMGQDOGUGBNIHE-UHFFFAOYSA-N 0.000 description 1
- JTZRPWNKLZJZFB-UHFFFAOYSA-N CC(C(COC1CC2NC)N1C2=O)=O Chemical compound CC(C(COC1CC2NC)N1C2=O)=O JTZRPWNKLZJZFB-UHFFFAOYSA-N 0.000 description 1
- AUFZRNJYCVYWAN-UHFFFAOYSA-N CC(C(CSC1CC2NC)N1C2=O)=O Chemical compound CC(C(CSC1CC2NC)N1C2=O)=O AUFZRNJYCVYWAN-UHFFFAOYSA-N 0.000 description 1
- SJEZIHPCSCLGGK-UHFFFAOYSA-N CC(C1N(C)C2NC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CCCC3)C3C2C1)=O SJEZIHPCSCLGGK-UHFFFAOYSA-N 0.000 description 1
- WYVCVCNDHCXMPG-UHFFFAOYSA-N CC(C1N(C)C2NC(CCNC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CCNC3)C3C2C1)=O WYVCVCNDHCXMPG-UHFFFAOYSA-N 0.000 description 1
- LERQTEOOMKVSKM-UHFFFAOYSA-N CC(C1N(C)C2NC(CNCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2NC(CNCC3)C3C2C1)=O LERQTEOOMKVSKM-UHFFFAOYSA-N 0.000 description 1
- GZBPEQHESSJRPW-UHFFFAOYSA-N CC(C1N(C)C2NC3NCCCC3C2C1)=O Chemical compound CC(C1N(C)C2NC3NCCCC3C2C1)=O GZBPEQHESSJRPW-UHFFFAOYSA-N 0.000 description 1
- LEWRGDPKNRUOBT-UHFFFAOYSA-N CC(C1N(C)C2Nc3cccnc3C2C1)=O Chemical compound CC(C1N(C)C2Nc3cccnc3C2C1)=O LEWRGDPKNRUOBT-UHFFFAOYSA-N 0.000 description 1
- BVVCPCIUYCENAS-UHFFFAOYSA-N CC(C1N(C)C2OC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2OC(CCCC3)C3C2C1)=O BVVCPCIUYCENAS-UHFFFAOYSA-N 0.000 description 1
- FDIKJQSLNVXCGP-UHFFFAOYSA-N CC(C1N(C)C2SC(CCCC3)C3C2C1)=O Chemical compound CC(C1N(C)C2SC(CCCC3)C3C2C1)=O FDIKJQSLNVXCGP-UHFFFAOYSA-N 0.000 description 1
- UGXICRZJJBNLES-UHFFFAOYSA-N CC(C1N(C)CC2C1C1CC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1CC2CC1)=O UGXICRZJJBNLES-UHFFFAOYSA-N 0.000 description 1
- AZZDJWMTNMLXTE-UHFFFAOYSA-N CC(C1N(C)CC2C1C1NC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1NC2CC1)=O AZZDJWMTNMLXTE-UHFFFAOYSA-N 0.000 description 1
- DTXRKOMFJJIHQQ-UHFFFAOYSA-N CC(C1N(C)CC2C1C1SC2CC1)=O Chemical compound CC(C1N(C)CC2C1C1SC2CC1)=O DTXRKOMFJJIHQQ-UHFFFAOYSA-N 0.000 description 1
- MBYLCPNYNFPEGO-UHFFFAOYSA-N CC(C1N(C)CC2C1SCCC2)=O Chemical compound CC(C1N(C)CC2C1SCCC2)=O MBYLCPNYNFPEGO-UHFFFAOYSA-N 0.000 description 1
- OEKQXFLIHRRQRX-UHFFFAOYSA-N CC(C1N(C)Cc2c(cc3)[o]c3c12)=O Chemical compound CC(C1N(C)Cc2c(cc3)[o]c3c12)=O OEKQXFLIHRRQRX-UHFFFAOYSA-N 0.000 description 1
- NWTVYVJSHUOOCE-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2NC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2NC1)=O NWTVYVJSHUOOCE-UHFFFAOYSA-N 0.000 description 1
- APHUYPADINESLM-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2OC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2OC1)=O APHUYPADINESLM-UHFFFAOYSA-N 0.000 description 1
- ULSXBYJFOPUNQS-UHFFFAOYSA-N CC(C1N(CC(CC2)NC)C2SC1)=O Chemical compound CC(C1N(CC(CC2)NC)C2SC1)=O ULSXBYJFOPUNQS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51015603P | 2003-10-10 | 2003-10-10 | |
| US60/510,156 | 2003-10-10 | ||
| US51376803P | 2003-10-23 | 2003-10-23 | |
| US60/513,768 | 2003-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006115558A true RU2006115558A (ru) | 2007-11-20 |
Family
ID=34467967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006115558/04A RU2006115558A (ru) | 2003-10-10 | 2004-10-08 | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7208600B2 (enExample) |
| EP (2) | EP1692157B1 (enExample) |
| JP (2) | JP2007532474A (enExample) |
| KR (2) | KR20120010278A (enExample) |
| CN (1) | CN101857631A (enExample) |
| AU (1) | AU2004282148A1 (enExample) |
| CA (1) | CA2541634A1 (enExample) |
| IL (1) | IL174863A0 (enExample) |
| MX (1) | MXPA06004006A (enExample) |
| NO (1) | NO20062101L (enExample) |
| NZ (1) | NZ546663A (enExample) |
| RU (1) | RU2006115558A (enExample) |
| TW (1) | TW200528472A (enExample) |
| WO (1) | WO2005037860A2 (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227742B1 (en) * | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| EP1268519B1 (en) * | 2000-04-03 | 2005-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| EP1613620A1 (en) * | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| CN102020700A (zh) | 2003-07-18 | 2011-04-20 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
| PE20050374A1 (es) * | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
| TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| EP1692157B1 (en) * | 2003-10-10 | 2013-04-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| EP1677827B1 (en) * | 2003-10-27 | 2008-12-10 | Vertex Pharmaceuticals Incorporated | Combinations for hcv treatment |
| CN1938332B (zh) * | 2004-02-04 | 2011-10-19 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101263156A (zh) | 2005-07-25 | 2008-09-10 | 因特蒙公司 | C型肝炎病毒复制的新颖大环抑制剂 |
| RU2441020C2 (ru) * | 2005-08-02 | 2012-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы серинпротеазы |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) * | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| CN101415705B (zh) | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| EP2194039A1 (en) | 2006-03-16 | 2010-06-09 | Vertex Pharmceuticals Incorporated | Process for preparing optically enriched compounds |
| WO2007133865A2 (en) * | 2006-04-11 | 2007-11-22 | Novartis Ag | Hcv/hiv inhibitors an their uses |
| EP2027143A2 (en) | 2006-05-23 | 2009-02-25 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA016327B1 (ru) | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| BRPI0807907A2 (pt) | 2007-02-27 | 2017-05-16 | Vertex Pharma | co-cristais e composições farmacêuticas compreendendo os mesmos. |
| CN101903392A (zh) * | 2007-02-27 | 2010-12-01 | 弗特克斯药品有限公司 | 丝氨酸蛋白酶的抑制剂 |
| EP2160392A2 (en) * | 2007-05-03 | 2010-03-10 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2008141227A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| TW200922933A (en) | 2007-08-30 | 2009-06-01 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| EP2237666A4 (en) | 2007-12-21 | 2012-05-16 | Avila Therapeutics Inc | HCV PROTEASE INHIBITORS AND USES THEREOF |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| CN104557861A (zh) | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8101567B2 (en) * | 2008-01-24 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Heteroaryl-containing tripeptide HCV serine protease inhibitors |
| CN101977915B (zh) | 2008-02-04 | 2014-08-13 | 埃迪尼克斯医药公司 | 大环丝氨酸蛋白酶抑制剂 |
| BRPI0911260A2 (pt) * | 2008-04-15 | 2015-09-29 | Intermune Inc | composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2307434B1 (en) | 2008-07-02 | 2014-02-12 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20110075019A (ko) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | 치료용 항바이러스성 펩티드 |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8073632B2 (en) * | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス，インコーポレイテッド | ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤 |
| JP2012523419A (ja) | 2009-04-08 | 2012-10-04 | イデニク プハルマセウティカルス，インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| JP2013501068A (ja) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
| WO2011038293A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
| US20110082182A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
| US8362068B2 (en) | 2009-12-18 | 2013-01-29 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2012308900A1 (en) | 2011-09-12 | 2013-05-09 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
| BR112014029115A8 (pt) | 2012-05-22 | 2018-04-03 | Idenix Pharmaceuticals Inc | Composto, composição farmacêutica, e, uso de um composto ou composição |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
| BR112015007698A2 (pt) | 2012-10-08 | 2017-08-22 | Idenix Pharmaceuticals Inc Centre National De La Recherche Scientifique E Univ Montpellier 2 Science | Composto, composição farmacêutica, e, uso de um composto |
| WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
| WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
| US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
| EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
| EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
| EP3114122A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| WO2015134780A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| KR102568859B1 (ko) * | 2015-02-13 | 2023-08-21 | 옥스포드 드러그 디자인 리미티드 | 아미노아실-tRNA 합성효소 저해제로서 신규한 N-아실-아릴술폰아미드 유도체 |
| CN118994191A (zh) | 2016-02-05 | 2024-11-22 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
| GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| EP3860636A4 (en) * | 2018-10-02 | 2022-06-22 | Disc Medicine, Inc. | MATRIPTASE 2 INHIBITORS AND THEIR USES |
| CN113167802B (zh) | 2018-12-04 | 2025-02-07 | 百时美施贵宝公司 | 通过多同位素体反应监测使用样品内校准曲线的分析方法 |
| CA3148310A1 (en) * | 2019-09-13 | 2021-03-18 | Jun Qi | Kdm inhibitors and uses thereof |
| AU2023206890A1 (en) | 2022-01-12 | 2024-08-22 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1090914B1 (en) | 1992-12-29 | 2003-01-02 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| HUT72440A (en) * | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| WO1997040028A1 (en) | 1996-04-23 | 1997-10-30 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| EP0907659A1 (en) | 1996-05-10 | 1999-04-14 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
| HU227742B1 (en) * | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| CA2282398A1 (en) | 1997-03-14 | 1998-09-17 | Steven M. Ronkin | Inhibitors of impdh enzyme |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| NZ503263A (en) | 1997-08-11 | 2002-10-25 | Boehringer Ingelheim Ca Ltd | Hepatitis C NS3 protease inhibitor peptides and peptide analogues |
| JP4354632B2 (ja) | 1997-08-11 | 2009-10-28 | ベーリンガー インゲルハイム （カナダ） リミテッド | Ｃ型肝炎抑制剤ペプチド |
| IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
| ES2281170T3 (es) * | 1998-03-31 | 2007-09-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c. |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
| GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
| WO2000056331A1 (en) | 1999-03-19 | 2000-09-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| EP1206449A1 (en) | 1999-07-26 | 2002-05-22 | Bristol-Myers Squibb Company | Lactam inhibitors of hepatitis c virus ns3 protease |
| US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
| US6699855B2 (en) | 2000-02-29 | 2004-03-02 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
| EP1268519B1 (en) * | 2000-04-03 | 2005-06-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| DE60137207D1 (de) | 2000-04-05 | 2009-02-12 | Schering Corp | Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen |
| SK14952002A3 (sk) | 2000-04-19 | 2003-03-04 | Schering Corporation | Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie |
| NZ523781A (en) | 2000-07-21 | 2004-10-29 | Corvas Int Inc | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| RU2355700C9 (ru) | 2000-07-21 | 2010-03-20 | Шеринг Корпорейшн | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
| WO2002048157A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
| AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
| KR100926244B1 (ko) | 2001-07-11 | 2009-11-12 | 버텍스 파마슈티칼스 인코포레이티드 | 브릿지된 바이사이클릭 세린 프로테아제 억제제 |
| EP1441720B8 (en) * | 2001-10-24 | 2012-03-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| MXPA04009938A (es) * | 2002-04-11 | 2004-12-13 | Vertex Pharma | Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv. |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| CA2515216A1 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
| DE10315645B4 (de) | 2003-04-04 | 2005-07-14 | Zf Boge Elastmetall Gmbh | Hydraulisch dämpfendes Gummibuchsenlager für vertikale Montage |
| EP1613620A1 (en) * | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| CA2521678A1 (en) * | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| AU2004233757B2 (en) | 2003-05-01 | 2007-08-02 | The Procter & Gamble Company | Striped liquid personal cleansing compositions containing a cleansing phase and a separate benefit phase comprising a water in oil emulsion |
| CL2004001161A1 (es) * | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| CN102020700A (zh) * | 2003-07-18 | 2011-04-20 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
| PE20050374A1 (es) * | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
| TW200526686A (en) * | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| EP1692157B1 (en) * | 2003-10-10 | 2013-04-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| CN1938332B (zh) * | 2004-02-04 | 2011-10-19 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-08 EP EP04794554.8A patent/EP1692157B1/en not_active Expired - Lifetime
- 2004-10-08 KR KR1020117029638A patent/KR20120010278A/ko not_active Ceased
- 2004-10-08 EP EP10183579A patent/EP2361925A1/en not_active Withdrawn
- 2004-10-08 KR KR1020067006901A patent/KR20060130027A/ko not_active Ceased
- 2004-10-08 MX MXPA06004006A patent/MXPA06004006A/es active IP Right Grant
- 2004-10-08 NZ NZ546663A patent/NZ546663A/en not_active IP Right Cessation
- 2004-10-08 WO PCT/US2004/033238 patent/WO2005037860A2/en not_active Ceased
- 2004-10-08 CN CN201010183514A patent/CN101857631A/zh active Pending
- 2004-10-08 RU RU2006115558/04A patent/RU2006115558A/ru not_active Application Discontinuation
- 2004-10-08 JP JP2006534377A patent/JP2007532474A/ja active Pending
- 2004-10-08 AU AU2004282148A patent/AU2004282148A1/en not_active Abandoned
- 2004-10-08 CA CA002541634A patent/CA2541634A1/en not_active Abandoned
- 2004-10-08 TW TW093130680A patent/TW200528472A/zh unknown
- 2004-10-12 US US10/964,214 patent/US7208600B2/en not_active Expired - Fee Related
-
2006
- 2006-04-09 IL IL174863A patent/IL174863A0/en unknown
- 2006-05-10 NO NO20062101A patent/NO20062101L/no unknown
-
2007
- 2007-03-09 US US11/716,248 patent/US8039623B2/en not_active Expired - Fee Related
-
2011
- 2011-08-18 JP JP2011179106A patent/JP2011246487A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011246487A (ja) | 2011-12-08 |
| NO20062101L (no) | 2006-07-05 |
| US7208600B2 (en) | 2007-04-24 |
| WO2005037860A2 (en) | 2005-04-28 |
| IL174863A0 (en) | 2008-02-09 |
| KR20060130027A (ko) | 2006-12-18 |
| EP2361925A1 (en) | 2011-08-31 |
| JP2007532474A (ja) | 2007-11-15 |
| CN101857631A (zh) | 2010-10-13 |
| EP1692157B1 (en) | 2013-04-17 |
| EP1692157A2 (en) | 2006-08-23 |
| NZ546663A (en) | 2010-01-29 |
| AU2004282148A1 (en) | 2005-04-28 |
| CA2541634A1 (en) | 2005-04-28 |
| KR20120010278A (ko) | 2012-02-02 |
| WO2005037860A3 (en) | 2005-11-10 |
| US20050137140A1 (en) | 2005-06-23 |
| TW200528472A (en) | 2005-09-01 |
| US20070161789A1 (en) | 2007-07-12 |
| MXPA06004006A (es) | 2006-06-28 |
| US8039623B2 (en) | 2011-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006115558A (ru) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы | |
| RU2006105002A (ru) | Ингибиторы сериновых протеаз, в частности, нс-3-нс4а протеазы | |
| RU2006110934A (ru) | 2-амидо-4-арилокси-1-карбонилпирролидиновые производные в качестве ингибиторов серинпротеаз, в частности, протеазы ns3-ns4a hcv | |
| JP2007532474A5 (enExample) | ||
| RU2004133044A (ru) | Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv | |
| RU2008108024A (ru) | Ингибиторы серинпротеазы | |
| JP2005535574A5 (enExample) | ||
| WO2005035525B1 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| RU2010135497A (ru) | Ингибирование протеазы ns3-ns4 вируса hcv | |
| ES2381548T3 (es) | Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A | |
| AU721079B2 (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders | |
| JP2007504251A5 (enExample) | ||
| AR045769A1 (es) | Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c) | |
| MX2011006239A (es) | Analogos ciclicos de peptido de 4-amino-4-oxobutanoilo, inhibidores de replica viral. | |
| US20040138109A1 (en) | Potent inhibitor of HCV serine protease | |
| JP2009506078A5 (enExample) | ||
| KR20000049263A (ko) | 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ３ 프로테아제의억제제 | |
| EA007739B1 (ru) | Гетероциклические трипептиды в качестве ингибиторов вируса гепатита с | |
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| JP2008514690A (ja) | Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物 | |
| JP2009505966A5 (enExample) | ||
| CA2747636A1 (en) | Hcv ns3 protease inhibitors | |
| JP5049788B2 (ja) | ウイルス感染症を処置するためのアンドログラフォライド（ａｎｄｒｏｇｒａｐｈｏｌｉｄｅ）誘導体 | |
| US20110064694A1 (en) | Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues | |
| WO2013178782A1 (en) | Allosteric inhibitors of ns3 protease from hepatitis c virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20071211 |